Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
ESC 2002 ESC 2002 Valentin Fuster MD Director, Cardiovascular Institute Mount Sinai Medical Center New York, NY Christopher Cannon MD Cardiologist Brigham and Women's Hospital Boston, MA James Ferguson MD Associate Director, Cardiology St Luke's Episcopal Hospital and Texas Heart Institute Houston, TX Michael Weber MD Professor of Medicine SUNY Downstate College of Medicine Heartbeat – Sep 2002 Brooklyn, NY ESC 2002 Topics Acute coronary syndromes MAGIC OPTIMAAL RITA-3 BNP prognostics Off-pump surgery Stem cells Heartbeat – Sep 2002 ESC 2002 MAGIC: Trial design MAGnesium In Coronaries (MAGIC) PI: Elliot Antman • 6213 MI patients. • Randomized to IV magnesium or placebo. • Primary end point: all-cause mortality at 30 days. Heartbeat – Sep 2002 ESC 2002 MAGIC: Mortality results 20% No difference in 30-day mortality between magnesium and placebo. 18% 16% 14% 12% No significant differences in any subgroup. 10% 8% No benefit or harm seen in secondary outcomes. 6% 4% 2% 0% Death “Magnesium is dead in the water.” Rory Collins Mg Heartbeat – Sep 2002 Placebo ESC 2002 MAGIC: Time to move on There were intriguing questions generated by earlier trials. “But when you put it to the test, it doesn’t make any difference. So, let’s move on.” Ferguson Heartbeat – Sep 2002 ESC 2002 MAGIC: Rationale for the trial LIMIT-2: Mg started before thrombolysis. ISIS 4: Mg started several hours after thrombolysis. The negative results in ISIS-4 could have been due to the delay. MAGIC went back to early administration of Mg. Cannon Heartbeat – Sep 2002 ESC 2002 MAGIC: A might-have-been? Did magnesium never have a chance because ACE inhibitors and thrombolysis got there first? “We really don’t have any information that would allow us to make that judgment.” Weber Heartbeat – Sep 2002 ESC 2002 OPTIMAAL: Trial design Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan (OPTIMAAL) PI: Kenneth Dickstein • 5477 patients. • Acute MI. • Losartan 50 mg once daily vs captopril 50 mg 3 times daily mm Hg. • Primary end point: all-cause mortality at 2.7 years follow-up. Heartbeat – Sep 2002 ESC 2002 OPTIMAAL: Results Rate of endpoint captopril 20% 18% 16% 14% 12% 10% 8% 6% 4% 2% 0% Heartbeat – Sep 2002 p=0.069 Mortality losartan p=0.032 CV death Lancet 360:752-760 ESC 2002 OPTIMAAL: ACE vs ARB The angiotensin axis is important, but ACE inhibitors are still superior to ARBs in the doses we’ve tested. New tools help, but losartan is still just a good alternative therapy. There is interest in higher doses of losartan. Heartbeat – Sep 2002 Ferguson ESC 2002 OPTIMAAL: A Greek tragedy The results were known well over a year ago. ELITE-2 also had a trend favoring captopril with the same doses. VAL-HeFT used a genuine dose (160 mg twice a day) of valsartan and got FDA approval for heart failure. 50 mg is a nonsense dose. Heartbeat – Sep 2002 Weber ESC 2002 OPTIMAAL: Misnamed The name is ironic because OPTIMAAL tested suboptimal levels of losartan. Dose is critical–-we haven’t tested proper doses of losartan yet. “The whole rationale in this field is moving toward complete blockade of this axis, so to use a very low dose goes counter to the thinking of how this pathway can be best inhibited and outcomes improved.” Heartbeat – Sep 2002 Cannon ESC 2002 OPTIMAAL: Appropriate dosing Losartan as a replacement for captopril should use a minimum of 100 mg. We should push the doses as high as one appropriately can because that goes after the pathophysiology of the problem. Cannon Heartbeat – Sep 2002 ESC 2002 OPTIMAAL: ARBs Losartan should be used at 50 mg bid. LIFE titrated patients from 50 mg a day to as much as 100 mg daily. The advantage in LIFE was a stroke advantage, not an MI advantage. “For all the excitement with the ARBs they’ve still got to prove themselves as having a cardioprotective effect.” Heartbeat – Sep 2002 Weber ESC 2002 RITA-3: Trial design Randomized Intervention Trial of unstable Angina (RITA-3) PI: Keith AA Fox • 1810 patients with non-ST-elevation Ml or unstable angina. • Randomized to conservative or interventional approach. • Primary end points: death, MI, and refractory angina at 4 months and death and MI at 1 year. Heartbeat – Sep 2002 ESC 2002 RITA-3: Defining risk Troponin is the most potent: high vs low risk (FRISC II). ST-segment changes on the EKG also gives high vs low risk. TIMI risk score ranges from 0 to 7, defining low-, intermediate-, and high-risk groups. TACTICS-TIMI 18 and FRISC II both found intermediate to high risk benefited from an early intervention strategy. Heartbeat – Sep 2002 Cannon ESC 2002 RITA-3: Heart failure as a risk factor Admission with heart failure is a very important predictor of death but a less important predictor of recurrent MI or recurrent ischemia. Markers of the burden of disease are more effective for predicting the broader impact of a therapy. Cannon Heartbeat – Sep 2002 ESC 2002 RITA-3: Moderate risk? Patients in RITA-3 are called moderate risk but: • 75% of the patients were troponin positive. • Exclusion criteria included 2x normal CK elevation. • The CK-negative/troponin-positive group is at highest risk of recurrent ischemic events. Heartbeat – Sep 2002 ESC 2002 RITA-3: Event rate Interventional Rate of endpoint 16% 14% 12% 10% p=0.001 14.5 Conservative p=0.58 9.6 7.6 8% 8.3 6% 4% 2% 0% Heartbeat – Sep 2002 4 months 1 year ESC 2002 ESC 2002 RITA-3: Trial comparison Interventional Conservative Death or MI in 1 year 25% 20% 15% 10% 5% 0% VANQWISH Heartbeat – Sep 2002 T-T 18 FRISC II RITA-3 ESC 2002 ESC 2002 RITA-3: More cath labs RITA-3 and TACTICS-TIMI used an early invasive approach, FRISC II a little later. “The hope is that this will really spur Canada and the European countries to start building some more cath labs and start talking with their health authorities to say this is way we can improve outcomes for a large group of patients.” Heartbeat – Sep 2002 Cannon ESC 2002 RITA-3: So many patients We should see cath rates in the 80% to 85% range if we follow evidence-based medicine: • Between 2/3 and 3/4 UA/NSTEMI patients are moderate to high risk. • Three million estimated UA/NSTEMI patients in Europe and the US. • Even in clinical trials, half the conservative therapy group goes on to cath eventually. Heartbeat – Sep 2002 Cannon ESC 2002 RITA-3: Angina Individual endpoint at 1 year Interventional Conservative 120 100 80 60 40 20 0 Heartbeat – Sep 2002 Death MI Refractory angina Lancet 360:743-751 ESC 2002 RITA-3: MI using standard definition Interventional Conservative Death MI Death or MI at 1 yr 18% 16% 14% 12% 10% 8% 6% 4% 2% 0% Heartbeat – Sep 2002 Death or MI Lancet 360:743-751 ESC 2002 RITA-3: Inadequate resources “Even in this country we do have a great inadequacy of resources.” Most of the hospitals in Brooklyn do not have the resources to get quickly to a cath lab and to provide the appropriate intervention. “This is a big problem over here as well.” Heartbeat – Sep 2002 Weber ESC 2002 RITA-3: Summary RITA-3 adds to the thinking that acute coronary syndromes fall more and more into the interventional arena. What will the economics of this mean to poorer countries? Fuster Heartbeat – Sep 2002 ESC 2002 BNP prognostics: Trial design BNP as a prognostic for sudden death in HF PI: Rudolf Berger • 452 ambulatory patients with LVEF ≤ 35%. • Primary end point: sudden death over 3 years. Heartbeat – Sep 2002 ESC 2002 BNP: Mortality results <2.11 2.11+ 20% 18% 16% A log BNP ≥ 2.11 was the only independent predictor of sudden death 14% 12% 10% 8% This could discriminate who is a candidate for an ICD 6% 4% 2% 0% Death Heartbeat – Sep 2002 ESC 2002 BNP: Prognostic tool The study is fascinating because this takes BNP from a diagnostic to a prognostic tool. Maybe we have to start monitoring BNP in our heart failure patients. Patients with so-called mild heart failure may be the people for whom this test would be particularly helpful. Heartbeat – Sep 2002 Weber ESC 2002 BNP: Screening patients With a 20% total mortality rate, it’s hard to say how “mild” the heart failure really is. The predictive nature of BNP is really intriguing because we are all looking for ways to stratify patients for ICD. “I’d like to see this extended and confirmed.” Heartbeat – Sep 2002 Ferguson ESC 2002 BNP: Questions about ICDs Patients with MI and low EF should receive ICDs, but we are still looking at ways to screen the patients who will most benefit. For cardiac failure not related to coronary artery disease, do we know if ICDs are even useful? Fuster Heartbeat – Sep 2002 ESC 2002 BNP: We need risk stratification We need tools to pick out the patients who would most benefit from ICDs, because the costs could be prohibitive. Risk stratification is the right strategy, as it was with ACS. I’m hoping BNP can be measured in MADIT II and in upcoming trials. Heartbeat – Sep 2002 Cannon ESC 2002 BNP: Two patients Myocardial infarction EF = 35% Dilated cardiomyopathy EF = 35% Heartbeat – Sep 2002 ESC 2002 BNP: Two patients Monitor the cardiomyopathy patient, maybe measure BNP levels, look for an indication to use an ICD. I don’t think this particular information really speaks to patients with AMI. It’s not clear what the proper approach should be. Heartbeat – Sep 2002 Weber ESC 2002 BNP: AMI BNP will rise in the first 8 to 12 hours to a peak and then gradually descend with treatment. Maybe we need to treat patients differently, depending on how recent their MI. “[BNP] is now the new CRP for heart failure and I think we’ll have much more information in the next 6 to 12 months.” Heartbeat – Sep 2002 Cannon ESC 2002 BNP: Physiology matters “It brings us back to the issue that physiology matters.” The metabolic pathways underlying this process is important. “We just don’t quite understand enough about it to figure out exactly what’s going on yet.” Heartbeat – Sep 2002 Ferguson ESC 2002 Off-pump CABG: Trial design Patency of Off-Pump CABG PI: Brompton group • 103 patients. • 54 off-pump, 49 conventional CABG. • Primary end point: graft patency at 3months. Heartbeat – Sep 2002 ESC 2002 Off-pump CABG: Patency results Off-pump On-pump 100% Not a significant finding 80% If the grafts are more occluded, are all the advantages of offpump surgery irrelevant? 60% 40% Do we need to look deeper into what is happening with offpump CABG? 20% 0% Heartbeat – Sep 2002 Patancy Fuster ESC 2002 Off-pump CABG: Suboptimal patency The most important thing is graft patency. “If it were me or my family member, I’d definitely go for the real thing.” “I suppose it’s a replay of the PCI story, that suboptimal stent deployment leads to suboptimal results.” Cannon Heartbeat – Sep 2002 ESC 2002 Off-pump CABG: Tweaking the technique We improved adjunctive therapy with PCI over time, we can do the same here. “I think that off-pump is here to stay. I think we may just need to tweak it and may need to do the larger-scale trials looking closely at patency but also making an effort to optimize the adjunctive therapy.” Heartbeat – Sep 2002 Ferguson ESC 2002 Off-pump CABG: Experience Two or 3 patients made all the difference in this trial. These results must be very dependent on the skill and experience of the surgeons. We might see no difference between off-pump and on-pump patency in 5 or 6 years “But I suspect that in a handful of years we’re going to see much more shift to the off-pump method.” Heartbeat – Sep 2002 Weber ESC 2002 Stem cells: Mode of delivery SYLVAIN’s PIC Heartbeat – Sep 2002 ESC 2002 Stem cells: Ventricular function Before cell therapy 3-month follow-up p 30+13 12+7 0.005 Infarct region as perfusion 174+99 defect (cm2) 128+71 0.016 Stroke volume index (mL/m2) 49+7 56+7 0.010 Infarction wall movement velocity (mm/s) 2.0+1.1 4.0+2.6 0.028 Function parameter Infarct region as functional defect* (%) *Percentage of hypokinetic, akinetic, or dyskinetic regions Heartbeat – Sep 2002 Strauer BE et al. Circulation 2002 ESC 2002 Stem cells: New cardiomyocytes Stromal-mesenchymal pathway Bone marrow Pluripotent cells Skeletal muscle, cardiomyocytes Heartbeat – Sep 2002 ESC 2002 Stem cells: Arrhythmia There are concerns about increased risk of arrhythmias with this technique. We need studies with more patients. “As we look at heart failure, as we look at acute myocardial infarction, I think [stem cell therapy] is an area that we’re going to be seeing an awful lot more from. ” Heartbeat – Sep 2002 Ferguson ESC 2002 Stem cells: A new hope “The whole field of acute MI has revolved around the need for early salvage because you can’t get the heart cells back. But if in fact you can repair the heart then it’s just a wonderful new hope.” Cannon Heartbeat – Sep 2002 ESC 2002 Summary: MAGIC Randomized MI patients to IV magnesium or placebo. Absolutely no effect on mortality at 30 days. “We have to forget about magnesium, at least for the next 25 years.” Fuster Heartbeat – Sep 2002 ESC 2002 Summary: OPTIMAAL Losartan 50 mg once daily vs captopril 50 mg 3 times daily. Trend favored captopril, but questions remain because the dose of losartan was so low. “The issue is not closed.” Fuster Heartbeat – Sep 2002 ESC 2002 Summary: RITA-3 NSTEMI/UA patients randomized to conservative or interventional approach. Intervention is much better than conservative therapy. “This really moves the field of acute coronary syndromes more and more toward the interventional area.” Heartbeat – Sep 2002 Fuster ESC 2002 Summary: BNP BNP was a predictor of sudden death in patients with chronic cardiac failure. This opens the possibility of screening patients for ICD use. The data don’t translate into AMI patients, where BNP levels are highly variable. Heartbeat – Sep 2002 Fuster ESC 2002 Summary: Off-pump surgery We all think off-pump surgery lets patients go home early and has fewer bleeding complications. Graft patency was better in the on-pump CABG patients. We need to follow this new technology closely. Heartbeat – Sep 2002 Fuster ESC 2002 Summary: Stem cells Injection of pluripotent bone-marrow cells into myocardium post-MI. No inflammatory response, potential improvement in ventricular function, but a possible increase in arrhythmia. Heartbeat – Sep 2002 Fuster ESC 2002 Final word: SOLVD Patients in the original SOLVD trial got 8 to 9 months of increased life expectancy from aggressive ACE inhibitor treatment. It just emphasizes how the newer modalities we talked about today may be the ones that will make a real difference for people with heart failure. Heartbeat – Sep 2002 Weber ESC 2002 Final word: Interventional strategy In the ACS arena, the invasive strategy has held up as the best management strategy. “Hopefully we’ll start to see a move toward more patients being referred appropriately for cardiac catheterization and probably a need for more cath labs.” Heartbeat – Sep 2002 Cannon ESC 2002 Final word: Dose “The dose of a given drug is almost as important as the drug itself.” We need to make sure we are dosing appropriately in our practice. It’s not just enough to be on the right drug, the dose must be the right dose. Heartbeat – Sep 2002 Cannon ESC 2002 Final word: 3 lessons 1: We need clinical trials: more and more important at meetings. 2: If you do trials, you need to do them right: dosing, logistics, understand the biology. 3: Care moves forward: We have a responsibility to take the information and apply it to real-world practice. Heartbeat – Sep 2002 Ferguson ESC 2002 ESC 2002: End Valentin Fuster MD Director, Cardiovascular Institute Mount Sinai Medical Center New York, NY Christopher Cannon MD Cardiologist Brigham and Women's Hospital Boston, MA James Ferguson MD Associate Director, Cardiology St Luke's Episcopal Hospital and Texas Heart Institute Houston, TX Michael Weber MD Professor of Medicine SUNY Downstate College of Medicine Heartbeat – Sep 2002 Brooklyn, NY